Summary
87.42 -0.51(-0.58%)09/06/2024
Cohen & Steers Inc. (CNS)
Cohen & Steers Inc. (CNS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.58 | -2.17 | 5.47 | 24.32 | 16.19 | 38.72 | 97.03 | 572.46 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 87.42 | |
| Open | 88.28 | |
| High | 88.74 | |
| Low | 86.96 | |
| Volume | 88,472 | |
| Change | -0.51 | |
| Change % | -0.58 | |
| Avg Volume (20 Days) | 108,411 | |
| Volume/Avg Volume (20 Days) Ratio | 0.82 | |
| 52 Week Range | 50.05 - 89.66 | |
| Price vs 52 Week High | -2.50% | |
| Price vs 52 Week Low | 74.67% | |
| Range | -0.97 | |
| Gap Up/Down | 0.05 | |
Fundamentals | ||
| Market Capitalization (Mln) | 4,419 | |
| EBIDTA | 166,396,000 | |
| PE Ratio | 27.5175 | |
| PEG Ratio | 4.5898 | |
| WallStreet Target Price | 69.00 | |
| Book Value | 7.6510 | |
| Earnings Per Share | 2.5700 | |
| EPS Estimate Current Quarter | 0.7100 | |
| EPS Estimate Next Quarter | 0.7400 | |
| EPS Estimate Current Year | 2.9100 | |
| EPS Estimate Next Year | 3.2900 | |
| Diluted EPS (TTM) | 2.5700 | |
| Revenues | ||
| Profit Marging | 0.2627 | |
| Operating Marging (TTM) | 0.3281 | |
| Return on asset (TTM) | 0.1532 | |
| Return on equity (TTM) | 0.2979 | |
| Revenue TTM | 486,264,992 | |
| Revenue per share TTM | 9.8430 | |
| Quarterly Revenue Growth (YOY) | -0.0270 | |
| Quarterly Earnings Growth (YOY) | -0.0420 | |
| Gross Profit (TTM) | 275,147,000 | |
| Dividends | ||
| Dividend Share | 2.3000 | |
| Dividend Yield | 0.0334 | |
| Valuations | ||
| Trailing PE | 27.5175 | |
| Forward PE | 22.5225 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 9.0859 | |
| Revenue Enterprise Value | 6.8188 | |
| EBITDA Enterprise Value | 18.1341 | |
| Shares | ||
| Shares Outstanding | 50,540,400 | |
| Shares Float | 26,896,084 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.10 | |
| Insider (%) | 46.94 | |
| Institutions (%) | 56.07 | |
09/04 09:05 EST - accesswire.com
CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
HOUSTON, TX / ACCESSWIRE / September 4, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY.
CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
HOUSTON, TX / ACCESSWIRE / September 4, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY.
08/28 17:14 EST - prnewswire.com
Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
NEW YORK , Aug. 28, 2024 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Closed-End Opportunity Fund, Inc. (NYSE: FOF) (the "Fund") with information regarding the sources of the distribution to be paid on August 30, 2024 and cumulative distributions paid fiscal year-to-date. In December 2021, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission.
Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
NEW YORK , Aug. 28, 2024 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Closed-End Opportunity Fund, Inc. (NYSE: FOF) (the "Fund") with information regarding the sources of the distribution to be paid on August 30, 2024 and cumulative distributions paid fiscal year-to-date. In December 2021, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission.
08/28 17:08 EST - prnewswire.com
Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
NEW YORK , Aug. 28, 2024 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Total Return Realty Fund, Inc. (NYSE: RFI) (the "Fund") with information regarding the sources of the distribution to be paid on August 30, 2024 and cumulative distributions paid fiscal year-to-date. In December 2011, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission.
Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
NEW YORK , Aug. 28, 2024 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Total Return Realty Fund, Inc. (NYSE: RFI) (the "Fund") with information regarding the sources of the distribution to be paid on August 30, 2024 and cumulative distributions paid fiscal year-to-date. In December 2011, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission.
08/28 17:05 EST - prnewswire.com
Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
NEW YORK , Aug. 28, 2024 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers REIT and Preferred and Income Fund, Inc. (NYSE: RNP) (the "Fund") with information regarding the sources of the distribution to be paid on August 30, 2024 and cumulative distributions paid fiscal year-to-date. In December 2017, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission.
Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
NEW YORK , Aug. 28, 2024 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers REIT and Preferred and Income Fund, Inc. (NYSE: RNP) (the "Fund") with information regarding the sources of the distribution to be paid on August 30, 2024 and cumulative distributions paid fiscal year-to-date. In December 2017, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission.
08/28 16:51 EST - prnewswire.com
Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
NEW YORK , Aug. 28, 2024 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Infrastructure Fund, Inc. (NYSE: UTF) (the "Fund") with information regarding the sources of the distribution to be paid on August 30, 2024 and cumulative distributions paid fiscal year-to-date. In March 2015, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission.
Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
NEW YORK , Aug. 28, 2024 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Infrastructure Fund, Inc. (NYSE: UTF) (the "Fund") with information regarding the sources of the distribution to be paid on August 30, 2024 and cumulative distributions paid fiscal year-to-date. In March 2015, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission.
08/27 09:10 EST - accesswire.com
CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Live webcast on Wednesday, August 28th at 3:20 PM ET HOUSTON, TX / ACCESSWIRE / August 27, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will present and discuss recent corporate events at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, August 28, 2024 at 3:20 PM ET.
CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Live webcast on Wednesday, August 28th at 3:20 PM ET HOUSTON, TX / ACCESSWIRE / August 27, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will present and discuss recent corporate events at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, August 28, 2024 at 3:20 PM ET.
08/22 09:15 EST - accesswire.com
CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment
Live moderated webcast with John Climaco, Chief Executive Officer of CNS Pharmaceuticals on Monday, August 26th at 12:00 PM ET Participants have the ability to submit questions live during the Q&A portion of the segment or pre-submit questions in advan ce of the segment by emailing cnsp@jtcir.com HOUSTON, TX / ACCESSWIRE / August 22, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will participate in a Virtual Investor CEO Connect segment on Monday, August 26, 2024 at 12:00 PM ET. As part of the virtual event, Mr.
CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment
Live moderated webcast with John Climaco, Chief Executive Officer of CNS Pharmaceuticals on Monday, August 26th at 12:00 PM ET Participants have the ability to submit questions live during the Q&A portion of the segment or pre-submit questions in advan ce of the segment by emailing cnsp@jtcir.com HOUSTON, TX / ACCESSWIRE / August 22, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will participate in a Virtual Investor CEO Connect segment on Monday, August 26, 2024 at 12:00 PM ET. As part of the virtual event, Mr.
08/22 07:00 EST - prnewswire.com
Corero Network Security Expands Strategic Partnerships in Latin America with New Agreements and Client Wins in Chile
MARLBOROUGH, Mass. , Aug. 22, 2024 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQB: DDOSF), the distributed denial of service (DDoS) protection specialists, today announced the signing of three new strategic partner agreements in Chile with NovaRed, Vista Group International Ltd (VGL), and GreyMatter.
Corero Network Security Expands Strategic Partnerships in Latin America with New Agreements and Client Wins in Chile
MARLBOROUGH, Mass. , Aug. 22, 2024 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQB: DDOSF), the distributed denial of service (DDoS) protection specialists, today announced the signing of three new strategic partner agreements in Chile with NovaRed, Vista Group International Ltd (VGL), and GreyMatter.
08/19 08:00 EST - prnewswire.com
Cohen & Steers Appoints Lisa Dolly to Board of Directors
NEW YORK , Aug. 19, 2024 /PRNewswire/ -- Cohen & Steers, Inc.'s (NYSE: CNS) Board of Directors has appointed Lisa Dolly as a director of the company. Ms. Dolly has also been appointed as a member of the Board's Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.
Cohen & Steers Appoints Lisa Dolly to Board of Directors
NEW YORK , Aug. 19, 2024 /PRNewswire/ -- Cohen & Steers, Inc.'s (NYSE: CNS) Board of Directors has appointed Lisa Dolly as a director of the company. Ms. Dolly has also been appointed as a member of the Board's Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.
08/15 08:00 EST - accesswire.com
CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results
Potentially pivotal GBM study evaluating lead program, Berubicin, enrollment completed; Topline data expected in the first half of 2025 Recent strategic in-license of TPI 287 is highly synergistic with the ongoing potentially pivotal Berubicin program and demonstrates further commitment to changing the treatment paradigm in GBM Company plans to engage the U.S. FDA to seek guidance on advancing TPI 287 into a potential registration study for recurrent GBM Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure HOUSTON, TX / ACCESSWIRE / August 15, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the second quarter 2024 ended June 30, 2024. "It has been an important year for CNS Pharmaceuticals with completion of enrollment in our Berubicin trial, and more recently, our in-licensing of a highly synergistic asset for development, TPI 287.
CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results
Potentially pivotal GBM study evaluating lead program, Berubicin, enrollment completed; Topline data expected in the first half of 2025 Recent strategic in-license of TPI 287 is highly synergistic with the ongoing potentially pivotal Berubicin program and demonstrates further commitment to changing the treatment paradigm in GBM Company plans to engage the U.S. FDA to seek guidance on advancing TPI 287 into a potential registration study for recurrent GBM Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure HOUSTON, TX / ACCESSWIRE / August 15, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the second quarter 2024 ended June 30, 2024. "It has been an important year for CNS Pharmaceuticals with completion of enrollment in our Berubicin trial, and more recently, our in-licensing of a highly synergistic asset for development, TPI 287.
08/14 14:00 EST - globenewswire.com
Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative and lysosomal storage diseases, today announced publication of nonclinical data in the August 14, 2024 issue of Science Translational Medicine (link) demonstrating the ability of the Oligonucleotide Transport Vehicle (OTV) platform to achieve broad biodistribution of antisense oligonucleotides (ASOs) in the central nervous system (CNS) and skeletal and cardiac muscle following intravenous (IV) administration.
Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative and lysosomal storage diseases, today announced publication of nonclinical data in the August 14, 2024 issue of Science Translational Medicine (link) demonstrating the ability of the Oligonucleotide Transport Vehicle (OTV) platform to achieve broad biodistribution of antisense oligonucleotides (ASOs) in the central nervous system (CNS) and skeletal and cardiac muscle following intravenous (IV) administration.
08/13 07:30 EST - globenewswire.com
Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference
Plus' CNSide leptomeningeal metastases (LM) FORSEE trial met key primary and secondary endpoints CNSide more than doubled the diagnostic sensitivity vs. gold standard cerebral spinal fluid (CSF) cytology and influenced clinical management decisions in over 90% of LM cases AUSTIN, Texas, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, presented data from the FORESEE study of its CNSide platform for the diagnosis and management of LM.
Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference
Plus' CNSide leptomeningeal metastases (LM) FORSEE trial met key primary and secondary endpoints CNSide more than doubled the diagnostic sensitivity vs. gold standard cerebral spinal fluid (CSF) cytology and influenced clinical management decisions in over 90% of LM cases AUSTIN, Texas, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, presented data from the FORESEE study of its CNSide platform for the diagnosis and management of LM.
08/12 07:30 EST - globenewswire.com
Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference
Respect-LM dosing shows continued feasibility and safety of up to 44 mCi of intrathecal Rhenium ( 186 Re) Obisbemeda High absorbed radiation doses, mean circulating tumor cell reductions, and median overall survival of 12 months continue to show clinical promise AUSTIN, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, presented data in a podium presentation updating the progress of its ReSPECT-LM clinical trial of Rhenium (186Re) Obisbemeda (Rhenium Nanoliposome, 186RNL) in leptomeningeal disease (LM). The data were presented at the 2024 Society for NeuroOncology (SNO)/American Society for Clinical Oncology (ASCO) CNS Metastases Conference August 8-10, 2024 in Denver, Colorado.
Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference
Respect-LM dosing shows continued feasibility and safety of up to 44 mCi of intrathecal Rhenium ( 186 Re) Obisbemeda High absorbed radiation doses, mean circulating tumor cell reductions, and median overall survival of 12 months continue to show clinical promise AUSTIN, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, presented data in a podium presentation updating the progress of its ReSPECT-LM clinical trial of Rhenium (186Re) Obisbemeda (Rhenium Nanoliposome, 186RNL) in leptomeningeal disease (LM). The data were presented at the 2024 Society for NeuroOncology (SNO)/American Society for Clinical Oncology (ASCO) CNS Metastases Conference August 8-10, 2024 in Denver, Colorado.
08/09 16:05 EST - prnewswire.com
Cohen & Steers Announces Changes to Realty Indexes
NEW YORK , Aug. 9, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today pending changes to its Global Realty Majors Portfolio Index (GRM) and International Realty Majors Portfolio Index (IRP), effective as of the close of business on August 16, 2024. Cohen & Steers Global Realty Majors Portfolio Index (GRM) Added component (symbol) Removed component (symbol) Stockland Corporation Ltd.
Cohen & Steers Announces Changes to Realty Indexes
NEW YORK , Aug. 9, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today pending changes to its Global Realty Majors Portfolio Index (GRM) and International Realty Majors Portfolio Index (IRP), effective as of the close of business on August 16, 2024. Cohen & Steers Global Realty Majors Portfolio Index (GRM) Added component (symbol) Removed component (symbol) Stockland Corporation Ltd.
08/09 09:15 EST - zacks.com
Cohen & Steers (CNS) July AUM Jumps 4.8% on Upbeat Markets
Cohen & Steers (CNS) witnesses a 4.8% rise in July AUM balance, driven by solid market appreciation.
Cohen & Steers (CNS) July AUM Jumps 4.8% on Upbeat Markets
Cohen & Steers (CNS) witnesses a 4.8% rise in July AUM balance, driven by solid market appreciation.
08/08 16:38 EST - prnewswire.com
Cohen & Steers Announces Preliminary Assets Under Management and Net Flows For July 2024
NEW YORK , Aug. 8, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $84.6 billion as of July 31, 2024, an increase of $3.9 billion from assets under management of $80.7 billion at June 30, 2024. The increase was due to market appreciation of $4.1 billion, partially offset by distributions of $153 million and net outflows of $45 million.
Cohen & Steers Announces Preliminary Assets Under Management and Net Flows For July 2024
NEW YORK , Aug. 8, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $84.6 billion as of July 31, 2024, an increase of $3.9 billion from assets under management of $80.7 billion at June 30, 2024. The increase was due to market appreciation of $4.1 billion, partially offset by distributions of $153 million and net outflows of $45 million.
08/01 16:15 EST - prnewswire.com
Cohen & Steers, Inc. Declares Quarterly Dividend
NEW YORK , Aug. 1, 2024 /PRNewswire/ -- The Board of Directors of Cohen & Steers, Inc. (NYSE: CNS) declared a cash dividend for the third quarter of 2024 in the amount of $0.59 per share of common stock payable on August 22, 2024 to stockholders of record as of the close of business on August 12, 2024. About Cohen & Steers Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions.
Cohen & Steers, Inc. Declares Quarterly Dividend
NEW YORK , Aug. 1, 2024 /PRNewswire/ -- The Board of Directors of Cohen & Steers, Inc. (NYSE: CNS) declared a cash dividend for the third quarter of 2024 in the amount of $0.59 per share of common stock payable on August 22, 2024 to stockholders of record as of the close of business on August 12, 2024. About Cohen & Steers Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions.
07/30 07:00 EST - accesswire.com
CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies
Strategic in-license from Cortice Bioscience is highly synergistic with the ongoing potentially pivotal Berubicin program and demonstrates further commitment to changing the treatment paradigm in GBM Drug candidate, TPI 287, awarded Orphan designation and studied in over 350 patients to date, including clinical trials as monotherapy and in combination with bevacizumab demonstrating encouraging clinical efficacy and safety profile at target therapeutic doses Company plans to engage the U.S. FDA to seek guidance on advancing TPI 287 into a potential registration study for recurrent GBM Leveraging the significant clinical infrastructure and deep relationships established with the Neuro-Oncology community to expedite development of TPI 287 Company launches new corporate brand and website to more closely align with its unwavering commitment to addressing the most aggressive type of brain cancer, GBM, with an average survival of only 14 to 16 months after diagnosis and no cure Company to host live video webcast to discuss the transaction today, July 30 th at 8:30 AM ET HOUSTON, TX / ACCESSWIRE / July 30, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it has entered into an exclusive license agreement with Cortice Biosciences, Inc. ("Cortice"). The Company will host a live webcast presentation to discuss the transaction on Tuesday, July 30, 2024 at 8:30 AM ET (details below).
CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies
Strategic in-license from Cortice Bioscience is highly synergistic with the ongoing potentially pivotal Berubicin program and demonstrates further commitment to changing the treatment paradigm in GBM Drug candidate, TPI 287, awarded Orphan designation and studied in over 350 patients to date, including clinical trials as monotherapy and in combination with bevacizumab demonstrating encouraging clinical efficacy and safety profile at target therapeutic doses Company plans to engage the U.S. FDA to seek guidance on advancing TPI 287 into a potential registration study for recurrent GBM Leveraging the significant clinical infrastructure and deep relationships established with the Neuro-Oncology community to expedite development of TPI 287 Company launches new corporate brand and website to more closely align with its unwavering commitment to addressing the most aggressive type of brain cancer, GBM, with an average survival of only 14 to 16 months after diagnosis and no cure Company to host live video webcast to discuss the transaction today, July 30 th at 8:30 AM ET HOUSTON, TX / ACCESSWIRE / July 30, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it has entered into an exclusive license agreement with Cortice Biosciences, Inc. ("Cortice"). The Company will host a live webcast presentation to discuss the transaction on Tuesday, July 30, 2024 at 8:30 AM ET (details below).
07/25 09:05 EST - accesswire.com
CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference
HOUSTON, TX / ACCESSWIRE / July 25, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract has been selected for poster presentation at the 2024 SNO/ASCO CNS Cancer Conference being held August 8-10, 2024 in Denver, CO. Details of the presentation are as follows: Title: Use of a Brain-Penetrating Anthracycline in Anthracycline-Sensitive Brain Metastases: The Promise of Berubicin Presenter: Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals Abstract Code: RMTD-03 Category: Research Methods and Trial Design Considerations Date and Time: August 8, 2024 from 7:15 - 9:00 PM MT Location: Plaza Exhibit Hall, Sheraton Denver Downtown Hotel For more information about the event, please visit the conference website.
CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference
HOUSTON, TX / ACCESSWIRE / July 25, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract has been selected for poster presentation at the 2024 SNO/ASCO CNS Cancer Conference being held August 8-10, 2024 in Denver, CO. Details of the presentation are as follows: Title: Use of a Brain-Penetrating Anthracycline in Anthracycline-Sensitive Brain Metastases: The Promise of Berubicin Presenter: Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals Abstract Code: RMTD-03 Category: Research Methods and Trial Design Considerations Date and Time: August 8, 2024 from 7:15 - 9:00 PM MT Location: Plaza Exhibit Hall, Sheraton Denver Downtown Hotel For more information about the event, please visit the conference website.